



FUND OBJECTIVE

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

For informational purposes only. This document should be used to highlight some of the criteria to be used by index provider when publishing index constituents and is not comprehensive.

KEY FEATURES



High Growth Potential



Targeted Exposure



ETF Efficiency

SOLACTIVE CHINA BIOTECH INNOVATION INDEX

SELECTION

- The index is designed to track the performance of Chinese companies that are active in the field of biotechnology.
- Companies are only eligible for inclusion if:
 - They are headquartered in China or Hong Kong.
 - They are classified as "Biotechnology" by FactSet Industry.

SELECTION POOL

- Eligible companies must have:
 - Free Float Market Capitalization of \$200 million if they are not current index constituents and \$160 million if they are current constituents.
 - Average Daily Value Traded of at least \$2 million over the last six months if they are not current index constituents and \$1.4 million for existing constituents.
 - Listing on one of the following stock exchanges: Hong Kong Stock Exchange (HKSE), Shanghai-Hong Kong Stock Connect, Shenzhen-Hong Kong Stock Connect, New York Stock Exchange (NYSE) and NASDAQ.
 - Eligible securities include H-Shares, Red Chips, P-Chips, A-Shares, ADRs and common stocks with a primary listing on the NYSE or NASDAQ. If more than one share class of a company is in consideration for inclusion, only the most liquid is selected.

WEIGHTING SCHEME

- Index components are weighted according to their Free Float Market Capitalization:
 - Each component is subject to maximum weight of 8% and minimum weight of 0.3%.
 - The aggregate weight of the first companies with weight equal to or above 5% cannot exceed 40% of the index weight. The remaining companies are capped at 4.5%.

REBALANCING/REVIEWS

- The index follows a semi-annual rebalancing schedule. Rebalances are made on the second Friday of May and November each year.



For more information on the Index, please visit Solactive's website.

*For the complete and current index methodology please refer to the index provider's website. This summary document is accurate as of the time of its publication and Global X does not guarantee that it is current at any point thereafter.

The selection of the index constituents and their weighting is made by the index provider at its sole discretion.

Carefully consider the fund's investment objectives, risks, and charges and expenses. This and other information can be found in the fund's full or summary prospectus, which may be obtained by visiting globalxetfs.com. Please read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. A-Shares may be subject to frequent and widespread trading halts and may become illiquid. Trading suspensions in certain stock could lead to greater market execution risk and costs for the Fund, and the creation and redemption of Creation Units (as defined below) may also be disrupted. Technology companies and companies that rely heavily on technology tend to be more volatile than the overall market, and are also heavily dependent on patent and intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO) 1 Freedom Valley Drive, Oaks, PA, 19456, which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive, nor does Solactive make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive.